5HT3 Antagonism and Auditory Gating in Schizophrenia
Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: ondansetron (Drug); neuropsychological testing (Behavioral); nicotine (Drug); haloperidol (Drug)
Phase: N/A
Status: Completed
Sponsored by: Department of Veterans Affairs
Summary
The target groups in this study are brain waves and neurotransmitters (chemical messengers)
in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will
help understand more about normal brain functioning and how that functioning differs in
people with schizophrenia. Another purpose of this study is to determine how the altered
brain functioning in schizophrenia contributes the symptoms found in the illness.
Clinical Details
Official title: 5HT3 Antagonism and Auditory Gating in Schizophrenia
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Subjects with diagnosed with schizophrenia will be studied.
Locations and Contacts
VAMC, Denver, Colorado 80013, United States
Additional Information
Starting date: June 1998
Ending date: June 2003
Last updated: June 23, 2005
|
